These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 23850330)

  • 21. Amyloid biomarkers in Alzheimer's disease.
    Blennow K; Mattsson N; Schöll M; Hansson O; Zetterberg H
    Trends Pharmacol Sci; 2015 May; 36(5):297-309. PubMed ID: 25840462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.
    Parnetti L; Chiasserini D
    Biomark Med; 2011 Aug; 5(4):479-84. PubMed ID: 21861669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High performance plasma amyloid-β biomarkers for Alzheimer's disease.
    Nakamura A; Kaneko N; Villemagne VL; Kato T; Doecke J; Doré V; Fowler C; Li QX; Martins R; Rowe C; Tomita T; Matsuzaki K; Ishii K; Ishii K; Arahata Y; Iwamoto S; Ito K; Tanaka K; Masters CL; Yanagisawa K
    Nature; 2018 Feb; 554(7691):249-254. PubMed ID: 29420472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
    Cavedo E; Lista S; Khachaturian Z; Aisen P; Amouyel P; Herholz K; Jack CR; Sperling R; Cummings J; Blennow K; O'Bryant S; Frisoni GB; Khachaturian A; Kivipelto M; Klunk W; Broich K; Andrieu S; de Schotten MT; Mangin JF; Lammertsma AA; Johnson K; Teipel S; Drzezga A; Bokde A; Colliot O; Bakardjian H; Zetterberg H; Dubois B; Vellas B; Schneider LS; Hampel H
    J Prev Alzheimers Dis; 2014 Dec; 1(3):181-202. PubMed ID: 26478889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neurochemical markers of neurodegeneration in the early diagnosis of Alzheimer's disease, vascular and mixed dementia].
    Uspenskaia OV; Iakhno NN; Belushkina NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(8):36-40. PubMed ID: 20823828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.
    Somers C; Goossens J; Engelborghs S; Bjerke M
    Biomark Med; 2017 Feb; 11(2):169-178. PubMed ID: 28111962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
    Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
    J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.
    Nutu M; Zetterberg H; Londos E; Minthon L; Nägga K; Blennow K; Hansson O; Ohrfelt A
    Dement Geriatr Cogn Disord; 2013; 36(1-2):99-110. PubMed ID: 23860354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.
    Haldenwanger A; Eling P; Kastrup A; Hildebrandt H
    J Alzheimers Dis; 2010; 22(3):971-80. PubMed ID: 20858947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?
    Zetterberg H; Blennow K
    J Alzheimers Dis; 2013; 33 Suppl 1():S361-9. PubMed ID: 22710917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection.
    Risacher SL; Saykin AJ
    Annu Rev Clin Psychol; 2013; 9():621-48. PubMed ID: 23297785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reference measurement procedure for CSF amyloid beta (Aβ)
    Pannee J; Portelius E; Minthon L; Gobom J; Andreasson U; Zetterberg H; Hansson O; Blennow K
    J Neurochem; 2016 Nov; 139(4):651-658. PubMed ID: 27579672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid biomarkers for Alzheimer's disease.
    Blennow K; Zetterberg H
    J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease.
    Kulic L; Unschuld PG
    Curr Opin Neurol; 2016 Dec; 29(6):749-755. PubMed ID: 27805971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aminoterminally truncated and oxidized amyloid-β peptides in the cerebrospinal fluid of Alzheimer's disease patients.
    Bibl M; Gallus M; Welge V; Esselmann H; Wiltfang J
    J Alzheimers Dis; 2012; 29(4):809-16. PubMed ID: 22460324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of CSF markers in the early diagnosis of Alzheimer's disease].
    Vos SJ; Visser PJ; Verhey FR
    Tijdschr Psychiatr; 2011; 53(9):647-53. PubMed ID: 21898322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.
    Bjerke M; Engelborghs S
    J Alzheimers Dis; 2018; 62(3):1199-1209. PubMed ID: 29562530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.